Kite Pharma, Inc.
KITE evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Lead Asset:
- kite-796 (Phase 3)
What it means
What to watch
Prepared research question
What matters most for KITE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
kite-796 (Phase 3)
Next Catalyst
—
Tracking 2 pipeline candidates · 12 clinical trials for Kite Pharma, Inc..
Run Kite Pharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kite Pharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is Kite Pharma, Inc.'s lead drug candidate?
Kite Pharma, Inc.'s most advanced tracked candidate is kite-796 (Phase 3) for Chronic Inflammatory Demyelinating Polyneuropathy; Systemic Lupus Erythematosus; Solid and Hematological Malignancies.
Who is the CEO of Kite Pharma, Inc.?
Arie Belldegrun, M.D. is the chief executive officer of Kite Pharma, Inc. (KITE).
What therapeutic areas does Kite Pharma, Inc. focus on?
Kite Pharma, Inc. develops therapies across Oncology, Gene Therapy, Neurology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.